Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: A systematic review with meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 2, 2016, Pages 296-306

  Harris, Patrick N A ^a   Wei, Jane Y ^b   Shen, Andrew W ^b   Abdile, Ahmed A ^c   Paynter, Stuart ^b   Huxley, Rachel R ^b   Pandeya, Nirmala ^b   Doi, Yohei ^d   Huh, Kyungmin ^e   O'Neal, Catherine S ^f   Talbot, Thomas R ^g   Paterson, David L ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e Armed Forces Capital Hospital   (South Korea)

^f LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE AMPC; CARBAPENEM DERIVATIVE; CEFEPIME; CIPROFLOXACIN; DORIPENEM; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; QUINOLONE DERIVATIVE;

ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; CITROBACTER; DISEASE SEVERITY; DRUG EFFICACY; ENTEROBACTER; HUMAN; META ANALYSIS; MORTALITY; NONHUMAN; SERRATIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BACTEREMIA; ENTEROBACTERIACEAE INFECTIONS; SERRATIA INFECTIONS; SURVIVAL ANALYSIS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASE INHIBITORS; CARBAPENEMS; CEPHALOSPORINS; ENTEROBACTERIACEAE INFECTIONS; HUMANS; QUINOLONES; SERRATIA INFECTIONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84959909713     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv346     Document Type: Article

References (28)

1. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect 2013; 19: 501-9.
2. Jacoby GA. AmpC β-lactamases. Clin Microbiol Rev 2009; 22: 161-82.
3. Harris PN, Ferguson JK. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents 2012; 40: 297-305.
4. ChowJW, Fine MJ, ShlaesDM et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-90.
5. Choi SH, Lee JE, Park SJ et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC β-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 2008; 52: 995-1000.
6. Moher D, Liberati A, TetzlaffJ et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
7. Australian Group on Antimicrobial Resistance. Enterobacteriaceae Sepsis Outcome Programme (EnSOP) 2013 Antimicrobial Susceptibility Report. 2014. http://www.agargroup.org/files/AGAR%20EnSOP13%20Web%20Report%20FINAL%202.pdf.
8. Higgins JP, Ramsay C, Reeves BC et al. Issues relating to study design and risk of bias when including non-randomized studies in systematic reviews on the effects of interventions. Res Synth Methods 2013; 4: 12-25.
9. Siedner MJ, Galar A, Guzman-Suarez BB et al. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis 2014; 58: 1554-63.
10. Huh K, Kang CI, Kim J et al. Risk factors and treatment outcomes of bloodstream infection caused by extended-spectrum cephalosporinresistant Enterobacter species in adults with cancer. Diagn Microbiol Infect Dis 2014; 78: 172-7.
11. Chaubey VP, Pitout JD, Dalton B et al. Clinical and microbiological characteristics of bloodstreaminfections due to AmpC β-lactamase producing Enterobacteriaceae: an active surveillance cohort in a large centralized Canadian region. BMC Infect Dis 2014; 14: 647.
12. Hilty M, Sendi P, Seiffert SN et al. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: Is cefepime adequate therapy? Int J Antimicrob Agents 2013; 41: 236-49.
13. O'Neal CS, O'Neal HR, Daniels TL et al. Treatment outcomes in patients with third-generation cephalosporin-resistant Enterobacter bacteremia. Scand J Infect Dis 2012; 44: 726-32.
14. Marcos M, Inurrieta A, Soriano A et al. Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. J Antimicrob Chemother 2008; 62: 397-403.
15. Qureshi ZA, Paterson DL, Pakstis DL et al. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents 2011; 37: 26-32.
16. Lin TY, Chan MC, Yang YS et al. Clinical manifestations and prognostic factors of Morganella morganii bacteremia. Eur J Clin Microbiol Infect Dis 2015; 34: 231-6.
17. Tamma PD, Girdwood SC, Gopaul R et al. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis 2013; 57: 781-8.
18. Harris PN, Alder L, Paterson DL. Antimicrobial susceptibility reporting and treatment selection for AmpC-producing Enterobacteriaceae: what do microbiologists and infectious disease practitioners actually practice? Pathology 2015; 47: 386-8.
19. Armand-Lefevre L, Angebault C, Barbier F et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013; 57: 1488-95.
20. Weber SG, Gold HS, Hooper DC et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415-22.
21. Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-60.
22. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 2012; 18: 263-72.
23. Glasner C, Albiger B, Buist G et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 2013; 18: pii=20525.
24. IMP-4 in different genetic contexts in Enterobacteriaceae isolates from Australia. Antimicrob Agents Chemother 2008; 52: 2984-7.
25. IMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005; 41: 1549-56.
26. Wozniak A, Villagra NA, Undabarrena A et al. Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile. J Med Microbiol 2012; 61: 1270-9.
27. Lucasti C, Popescu I, Ramesh MK et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother 2013; 68: 1183-92.
28. Vazquez JA, Gonzalez Patzan LD, Stricklin D et al. Efficacy and safety of ceftazidime-avibactamversus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012; 28: 1921-31.